DRG 837 Chemotherapy with acute leukemia as secondary diagnosis or with high dose chemotherapy agent with mcc

Chemotherapy with acute leukemia as secondary diagnosis or with high dose chemotherapy agent with mcc

Chemotherapy with acute leukemia as secondary diagnosis or with high dose chemotherapy agent with mcc

C91.00  Acute lymphoblastic leukemia not having achieved remission

C91.01  Acute lymphoblastic leukemia, in remission

C91.02  Acute lymphoblastic leukemia, in relapse

C92.00  Acute myeloblastic leukemia, not having achieved remission

C92.01  Acute myeloblastic leukemia, in remission

C92.02  Acute myeloblastic leukemia, in relapse

C92.40  Acute promyelocytic leukemia, not having achieved remission

C92.41  Acute promyelocytic leukemia, in remission

C92.42  Acute promyelocytic leukemia, in relapse

C92.50  Acute myelomonocytic leukemia, not having achieved remission

C92.51  Acute myelomonocytic leukemia, in remission

C92.52  Acute myelomonocytic leukemia, in relapse

C92.60  Acute myeloid leukemia with 11q23-abnormality not having achieved remission

C92.61  Acute myeloid leukemia with 11q23-abnormality in remission

C92.62  Acute myeloid leukemia with 11q23-abnormality in relapse

C92.A0  Acute myeloid leukemia with multilineage dysplasia, not having achieved remission

C92.A1  Acute myeloid leukemia with multilineage dysplasia, in remission

C92.A2  Acute myeloid leukemia with multilineage dysplasia, in relapse

C93.00  Acute monoblastic/monocytic leukemia, not having achieved remission

C93.01  Acute monoblastic/monocytic leukemia, in remission

C93.02  Acute monoblastic/monocytic leukemia, in relapse

C94.00  Acute erythroid leukemia, not having achieved remission

C94.01  Acute erythroid leukemia, in remission

C94.02  Acute erythroid leukemia, in relapse

C95.00  Acute leukemia of unspecified cell type not having achieved remission

C95.01  Acute leukemia of unspecified cell type, in remission

C95.02  Acute leukemia of unspecified cell type, in relapse

Z08  Encounter for follow-up examination after completed treatment for malignant neoplasm

Z51.11  Encounter for antineoplastic chemotherapy

Z51.12  Encounter for antineoplastic immunotherapy